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Household transmission of Neisseria meningitidis in the 
meningitis belt
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Prevention, Atlanta, GA 30329, USA (SAM); and Norwegian Institute of Public Health, Oslo, 
Norway (PAK)
The epidemiology of Neisseria meningitidis is dynamic, with risk of meningococcal disease 
varying widely by region and depending on a confluence of host, organism, and 
environmental factors. Because transmission of N meningitidis results mainly in 
asymptomatic carriage, evaluation of oropharyngeal carriage can be helpful to understand 
the epidemiology and transmission of N meningitidis and, in turn, develop strategies for the 
prevention and control of meningococcal disease. The bacterium is transmitted through 
respiratory droplets and close contact, with transmission increasing in crowded settings such 
as military camps, universities, and schools.1 Household contacts of patients with 
meningococcal disease have been shown to be at increased risk of meningococcal carriage 
and disease in developed countries, where incidence of meningococcal disease is low and 
outbreaks infrequent. However, less is known about household transmission dynamics of N 
meningitidis in the unique epidemiological context of the meningitis belt of sub-Saharan 
Africa, which is characterised by high rates of endemic disease, annual outbreaks, and 
periodic large-scale epidemics, historically due to serogroup A meningococci.2
In The Lancet Global Health, Caroline Trotter and colleagues3 describe the importance of 
household transmission of N meningitidis in the meningitis belt using data from a series of 
cross-sectional meningococcal carriage surveys held across seven countries to describe 
meningococcal carriage and impact of a novel meningococcal serogroup A conjugate 
vaccine (MenAfriVac; Serum Institute of India PVT, Pune, India). Within the study the 
investigators recruited a subset of 184 households containing putative N meningitidis 
carriers due to any serogroup for longitudinal household carriage surveys carried out over 6 
months. 133 households with confirmed index carriers were compared with 51 control 
households in which N meningitidis in the putative index carrier was ruled out by reference 
testing. 21% (152 of 739) of individuals within index carrier households subsequently 
acquired N meninigitidis compared with 9% (35 of 371) of individuals in control 
households. Due to a paucity of serogroup A carriers, the impact of MenAfriVac vaccination 
on carriage acquisition or loss within households could not be determined. Although the 
overall carriage acquisition rate was 2·4% per month (95% CI 1·6–4·0), rates among all age 
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groups were four-to-five-times higher in households with an index carrier. Overall, the mean 
duration of carriage was 3·4 months (2·7–4·4). Index carriers were most likely to be 
adolescents, with a median age of 12 years, and children younger than 5 years were most 
likely to acquire carriage. In index carrier households, most individuals that subsequently 
developed carriage acquired the same or a similar strain as the index carrier, providing 
evidence for within-household transmission, although external acquisition was also noted. 
Further analysis of the strains with next-generation sequencing will be useful to further 
differentiate transmission within households versus external acquisition.
Since the progressive introduction of the meningococcal serogroup A conjugate vaccine in 
meningitis belt countries via mass vaccination campaigns of 1–29 year olds starting in 2010, 
a remarkable effect of the vaccine has been observed.4 Similar to other conjugate vaccines, 
MenAfriVac has demonstrated the ability to markedly reduce serogroup A N meningitidis 
carriage prevalence and generate herd immunity, likely contributing to the near-elimination 
of serogroup A disease in vaccinated areas.5,6 However, epidemics due to other serogroups, 
such as the 2015 serogroup C epidemics in Niger and Nigeria,7,8 continue to occur. Thus, 
additional strategies for the control of meningococcal disease are needed.
The findings of Trotter and colleagues3 provide further insight into transmission dynamics 
of N meningitidis within households in the meningitis belt. However, the low sensitivity rate 
of oropharyngeal swabbing (estimated as 57·8% [95% CI 53·5–62·0] in this study) is a 
limitation. Nevertheless, results of this evaluation along with surveillance data suggest that 
targeting school-age children and adolescents for vaccination with conjugate vaccines could 
provide maximum benefit in terms of direct protection and generation of herd immunity. 
Further household carriage evaluations specifically carried out during epidemics are needed 
to assess the relative importance of household transmission in the setting of widespread 
community transmission. Antibiotic chemoprophylaxis of household members of 
meningococcal disease cases is recommended in the meningitis belt outside of outbreaks,9 
although is rarely practiced due to resource and logistical constraints. Even though no 
known cases of meningococcal disease were reported in households participating in the 
study from Trotter and colleagues, the increased rate of subsequent carriage in index 
households supports this recommendation and efforts to improve its uptake. Additional 
evaluation of carriage among household contacts of a meningococcal case in both outbreak 
and non-outbreak settings would provide additional data to inform antibiotic 
chemoprophylaxis recommendations in the meningitis belt.
Despite the early successes of the MenAfriVac vaccine, endemic disease and epidemics due 
to serogroups C, W, and X continue to occur. Additional carriage evaluations will be helpful 
to continue to monitor the impact of MenAfriVac on serogroup A carriage as well as to 
support the development and evaluation of additional strategies for the control of 
meningococcal disease in this region.
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